Boston Life Sciences, Inc. Product Pipeline

(information and links below last updated: Winter 2005)

  © Boston Life Sciences. 2006. All rights reserved. Important Legal Notice



This site is protected by LetterDash.com, the attorney cease and desist letter platform.
If you violate any of our copyrights or trademarks,you will receive an official letter from our attorneys via LetterDash™.

We proudly engaged our marketing firm through:
Great Agencies - Marketplace for SEO and Digital Marketing Companies
(888) 222-8311
Located in the Sunnyvale City Center
support@greatagencies.com

Home | Company Profile | Product Pipeline | Patient Center | Investor Relations | Contact Us

ALTROPANE®

123 I-Based imaging agent for the early diagnosis of Parkinson's Disease (PD).

POET-1 Phase III trial ended early to evaluate full data set.  Results expected in Q3 2006.

ALTROPANE®

123 I-Based imaging agent for the objective diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)

Phase II

Inosine

Nerve growth factors for the treatment of stroke and spinal cord injury.

Pre-Clinical

FLUORATEC™

Technetium (99Tc) based imaging agent for the diagnosis of PD and ADHD

Pre-Clinical

O-1369

Novel DAT Blocker for the treatment of Parkinson's Disease

Pre-Clinical